First Oral Psoriatic Arthritis Drug Launched in Specialty Pharmacies
ReCept announced that it is one of the specialty pharmacies selected to distribute Otezla (apremilast; Celgene), a recently approved phosphodiesterase-4 (PDE-4) inhibitor for the treatment of adults with active psoriatic arthritis. Otezla is the first oral drug approved to treat active psoriatic arthritis.
Otezla is a PDE-4 inhibitor specific for cyclic adenosine monophosphate (cAMP). PDE4 inhibition results in increased intracellular cAMP levels. The specific mechanism(s) by which apremilast exerts its therapeutic action in psoriatic arthritis patients is not well defined.
Otezla is available in 60-count bottles (30mg tablets), a 13-tablet blister titration pack (10mg, 20mg, 30mg tablets), and two 14-count blister cards (30mg tablets).
For more information call (888) 771-0141 or visit Otezla.com.